GLP-1 receptor agonists like semaglutide and tirzepatide achieve 15% weight loss in clinical trials, approaching the 20-30% reductions seen with bariatric surgery that demonstrably lower obesity-related cancer risk over a decade. Given that obesity drives at least 13 cancer types and ranks as the second leading cancer cause after tobacco, these medications represent a potentially transformative population-level intervention. The biological rationale is compelling: sustained weight reduction appears to break the metabolic pathways linking adiposity to malignancy, including chronic inflammation, insulin resistance, and hormonal disruption. However, the authors highlight a critical research challenge—definitively proving cancer prevention benefit would require randomized trials spanning decades with enormous patient cohorts, making such studies practically and financially prohibitive. This creates a knowledge gap where promising mechanistic evidence meets methodological limitations. The emergence of these highly effective obesity medications coincides with growing recognition that intentional weight loss, not just weight stability, may be crucial for cancer prevention. While we await definitive cancer prevention data, the drugs' established cardiovascular and metabolic benefits already justify their use in appropriate patients.